BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update
PR Newswire —
Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/...